Dr Reddy’s has realized plans to introduce the two strengths of its generic version of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) in the US for which it holds 180-day generic exclusivity, as part of a complete six-strength offering.
The Indian firm’s launch, including lenalidomide 2.5mg and 20mg capsules with an exclusivity period, came as a glut of other...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?